Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Breast cancer乳腺癌

ICD-10: C50 — Malignant neoplasm of breast

Group: Cancer Specialty: Breast Surgery

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
乳腺癌
English name
Malignant neoplasm of breast

Values written in Chinese are quoted as published by the source.

Also known as

  • Breast carcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 18000 – 28430 CNY Condition package price 病种打包全包价 2020–2025
Radiotherapy 放疗 27000 – 45000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 6200 – 9000 CNY Condition package price 病种打包全包价 2020–2021
Targeted therapy 靶向 100000 – 195000 CNY Per-item price 项目价 2025
Immunotherapy 免疫 32043 – 42620 CNY Per-item price 项目价 2024–2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 195000 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 80.9% 95% CI 80.5–81.3

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    National key clinical specialty

    Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.

  2. Qilu Hospital of Shandong University山东大学齐鲁医院

    Jinan 济南市

    National key clinical specialty

    Published research

    3 more published studies

    PubMed indexes 5 papers on this condition that name this hospital.

    Also ranked: Gynecology #7 (tied), Otorhinolaryngology nominated, Gastroenterology nominated in the Fudan list.

  3. Shandong Cancer Hospital山东省肿瘤医院

    Jinan 济南市

    National key clinical specialty

  4. Hubei Cancer Hospital湖北省肿瘤医院

    Wuhan 武汉市

    National key clinical specialty

    Published research

    3 more published studies

    PubMed indexes 5 papers on this condition that name this hospital.

  5. Hunan Cancer Hospital湖南省肿瘤医院

    Changsha 长沙市

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Medical Oncology nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Breast cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05851014

  2. Study A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07673029

  3. Study A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy

    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07073755

  4. Study A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.

    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06734533

  5. Study A Prospective, Multigroup, Multi-center, Open-label Clinical Study of Trastuzumab Rezetecan as Neoadjuvant Therapy Combined With Toripalimab in HR+/HER2-low Breast Cancer Patients (NEOTORCH-BREAST 08)

    Hospital
    Third Affiliated Hospital of Harbin Medical University
    Status
    Recruiting
    Registry
    NCT07383818
98 more registered studies

  1. Study A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)

    Lead investigator
    Herui Yao · Principal Investigator
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT04263298

  2. Study A Randomized, Open-label, Multicenter Study Comparing Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT05292742

  3. Study Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study

    Lead investigator
    Tao OUYANG · Chairman of Breast Center of Peking University Cancer Hospital
    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT04481932

  4. Study Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial

    Lead investigator
    Gaosong Wu, Ph D, MD · Director
    Hospital
    Zhongnan Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT04665882

  5. Study A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06120283

  6. Study A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer

    Lead investigator
    Caigang Liu · Professor
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT05638594

  7. Study Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

    Lead investigator
    Jianyi Li · Principal Investigator
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT05346510

  8. Study A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer

    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT06178159

  9. Study Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer

    Lead investigator
    Xiaoli Yu · Professor
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT05479409

  10. Study A Cohort Study of Different Choice of Adjuvant Therapy in Non-PCR Patients With HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

    Lead investigator
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06693037

  11. Study A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

    Status
    Recruiting
    Registry
    NCT07071402

  12. Study Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

    Status
    Recruiting
    Registry
    NCT07012720

  13. Study A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

    Hospital
    Beijing Hospital
    Status
    Recruiting
    Registry
    NCT05950945

  14. Study Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06938373

  15. Study A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

    Lead investigator
    Jieqiong Liu, M.D., Ph.D. · Professor
    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06889688

  16. Study Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07616427

  17. Study A Randomized, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breast Cancer

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT07008976

  18. Study Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer

    Status
    Recruiting
    Registry
    NCT04353557

  19. Study A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients

    Lead investigator
    Tao Sun · Principal Investigator
    Hospital
    Liaoning Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07657130

  20. Study A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer

    Lead investigator
    HAN GUANG · professor
    Hospital
    Hubei Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06402435

  21. Study A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

    Lead investigator
    HAN GUANG · professor
    Hospital
    Hubei Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06401005

  22. Study Gut Microbiota Changes in Breast Cancer Patients Treated With Pyrotinib and Correlation With Drug-Induced Diarrhea: An Observational Cohort Study

    Lead investigator
    Xinhong Wu, PhD · vice-president
    Hospital
    Hubei Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07264985

  23. Study Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold for Left Sided Breast Cancer, A Real-World Study

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT06660628

  24. Study Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT06411678

  25. Study A Single-center, Blinded, Efficacious, Phase III Randomized Clinical Trial Initiated by Investigators to Investigate the Use of Surface Guided Radiation Therapy (SGRT) in Combination With Deep Inspiration Breath Hold (DIBH) Technique for Left Breast Cancer Treatment, Compared to Traditional Laser Alignment With Free Breathing Treatment

    Hospital
    Peking Union Medical College Hospital
    Status
    Recruiting
    Registry
    NCT05804916

  26. Study Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study

    Lead investigator
    Zhimin Shao · Professor
    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Status
    Recruiting
    Registry
    NCT04790305

  27. Study Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy

    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05326295

  28. Study A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05535413

  29. Study A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer

    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06276868

  30. Study Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer: a Prospective, Multicenter, Single Arm, Real World Study

    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06518135

  31. Study A Single-arm, Prospective, Open-label Phase II Clinical Study of Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05398861

  32. Study Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

    Lead investigator
    Zhenzhen Liu · Professor
    Hospital
    Henan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06860529

  33. Study Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With HER2 Negative Metastatic Breast Cancer Treated With Sacituzumab Govitecan: A Retrospective Trial in China（SACIT-OUT）

    Lead investigator
    Wang Xiaojia · MD
    Hospital
    Zhejiang Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06784921

  34. Study A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus PD-1 Inhibitors and Chemotherapy Versus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer

    Lead investigator
    Yongsheng Wang · Professor
    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06802757

  35. Study Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

    Hospital
    Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06977893

  36. Study A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

    Hospital
    China-Japan Friendship Hospital
    Status
    Recruiting
    Registry
    NCT06210776

  37. Study Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating

    Lead investigator
    Yong Yang · Chief physician
    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT05704166

  38. Study Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: a Phase III Randomized, Controlled Clinical Trial

    Lead investigator
    Yong Yang · M.D.
    Hospital
    Fujian Medical University Union Hospital
    Status
    Recruiting
    Registry
    NCT06559696

  39. Study A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07047365

  40. Study Efficacy and Safety of Probiotics Versus Standard Care in Preventing Diarrhea Induced by Neratinib in Breast Cancer Patients: A Prospective Randomized Controlled Clinical Trial

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06892093

  41. Study Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06278870

  42. Study Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Status
    Recruiting
    Registry
    NCT06916637

  43. Study A Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07347600

  44. Study An Interventional, Multicenter Study of Trastuzumab Rezetecan as Neoadjuvant Therapy in Patients With THP-Insensitive HER2-Positive Early Breast Cancer

    Lead investigator
    Hao Zhou · Associate Chief Physician
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07647263

  45. Study Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

    Lead investigator
    Caigang Liu · Principal Investigator
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT04137653

  46. Study The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer

    Lead investigator
    Caigang Liu · Director of oncology
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT06690645

  47. Study The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.

    Lead investigator
    Caigang Liu · Professor
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT05263570

  48. Study Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

    Lead investigator
    Caigang Liu · Principal Investigator
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT04136782

  49. Study The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

    Lead investigator
    Caigang Liu · director of oncology
    Hospital
    Shengjing Hospital
    Status
    Recruiting
    Registry
    NCT06698679

  50. Study A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06827236

  51. Study A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07498478

  52. Study Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial

    Lead investigator
    Zhong-yu Yuan · Clinical Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT04722978

  53. Study A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer: A Prospective Randomized Controlled Trial

    Lead investigator
    Kun Wang · Clinical Professor
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07352930

  54. Study A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

    Lead investigator
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT06811870

  55. Study Clinical Cohort Study of 21-gene Assay in Predicting the Prognosis of Elder Luminal-A Breast Cancer Patients With Axillary Lymph Node Metastasis

    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT06891651

  56. Study Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer

    Lead investigator
    Jian Zhang,MD · Director of Phase I clinical Research ward
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT06793332

  57. Study Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study

    Lead investigator
    Jian Zhang,MD · Director of Phase I Clinical Trial Department; Professor, Chief physician of oncology department
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Recruiting
    Registry
    NCT07134153

  58. Study A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

    Lead investigator
    Zhimin Shao · Chief Physician
    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05891093

  59. Study Cohort Study of Adjuvant Chemotherapy Combined With Targeted Therapy for Intermediate Risk HER2 Positive and Lymph Node Negative Early Breast Cancer

    Lead investigator
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Status
    Recruiting
    Registry
    NCT06711068

  60. Study A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

    Hospital
    Cancer Hospital of Chinese Academy of Medical Sciences
    Status
    Recruiting
    Registry
    NCT07679360

  61. Study IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT06926868

  62. Study A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06891833

  63. Study A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07043725

  64. Study The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study

    Lead investigator
    JIAYI CHEN · Chair of Radiation Oncology Department
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT06826885

  65. Study Prospective Randomized Controlled Study on Precision Irradiation of Regional Lymph Node for Clinical High-risk pN0 Breast Cancer

    Lead investigator
    JIAYI CHEN · Prof
    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT05976412

  66. Study Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial

    Lead investigator
    Chunyan Ma · Chief of Cardiovascular Ultrasound
    Hospital
    First Hospital of China Medical University
    Status
    Recruiting
    Registry
    NCT06282796

  67. Study Tolerability of Dalpiciclib Versus Abemaciclib/Ribociclib in Combination With Standard Endocrine Therapy for HR-Positive/HER2-Negative Early Breast Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Lead investigator
    Zhenzhen Liu · Professor
    Hospital
    Henan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07706933

  68. Study A Multicenter, Prospective, Randomized Two-arm Controlled Trial Comparing the Impact of Robotic Versus Endoscopic Surgery on Breast Nerve Function Following Nipple-sparing Mastectomy for Breast Cancer

    Lead investigator
    haiyanli · Chief Physician, Department of Breast Surgery
    Hospital
    Guangzhou Women and Children's Medical Center
    Status
    Not yet recruiting
    Registry
    NCT07850154

  69. Study Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

    Hospital
    The First Hospital of Jilin University
    Status
    Not yet recruiting
    Registry
    NCT06868017

  70. Study Efficacy and Safety of SHR-A1811 Versus Pyrotinib Plus Capecitabine in Patients With Trastuzumab Primary-Resistant HER2-Positive Advanced Breast Cancer：A Prospective, Multicenter, Open-Label, Randomized, Controlled Study

    Lead investigator
    Hanfang Jiang, MD · Professor
    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07417241

  71. Study A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients

    Lead investigator
    Jianyi Li · Chief Physician
    Hospital
    Shengjing Hospital
    Status
    Not yet recruiting
    Registry
    NCT07497191

  72. Study Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

    Lead investigator
    Caigang Liu · Director
    Hospital
    Shengjing Hospital
    Status
    Not yet recruiting
    Registry
    NCT04973319

  73. Study Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

    Lead investigator
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07077018

  74. Study A Prospective Study to Evaluate the Clinical Significance of Medical Humanities-based Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

    Lead investigator
    Jiong Wu · Principal Investigator
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Not yet recruiting
    Registry
    NCT06965556

  75. Study 针刺治疗激素受体阳性乳腺癌患者潮热的随机对照试验研究，A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

    Lead investigator
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07294339

  76. Study A Multicenter, Single-Arm, Open-Label Study of Extended Sentinel Lymph Node Biopsy Using Methylene Blue as a Single Tracer After Neoadjuvant Therapy in Patients With Axillary Node-Positive Breast Cancer

    Status
    Not yet recruiting
    Registry
    NCT07532096

  77. Study SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT06975475

  78. Study Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression: A Randomized Controlled Trial

    Lead investigator
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hospital
    Chinese PLA General Hospital
    Status
    Not yet recruiting
    Registry
    NCT07374198

  79. Study Effects of Acupuncture for Anxiety and/or Depression Among Patients With Breast Cancer

    Lead investigator
    Yuanjie Sun · Attending physician
    Hospital
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Status
    Not yet recruiting
    Registry
    NCT07183813

  80. Study Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study

    Hospital
    Zhejiang Hospital
    Status
    Not yet recruiting
    Registry
    NCT07188116

  81. Study A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

    Lead investigator
    Xuli Meng · Chief physician
    Hospital
    Zhejiang Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT06975644

  82. Study A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

    Hospital
    Hunan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07163481

  83. Study The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

    Lead investigator
    Wang Xiaojia · chief physician
    Hospital
    Zhejiang Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06140576

  84. Study A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.

    Lead investigator
    Jinming Yu · PhD, MD
    Hospital
    Shandong Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07187752

  85. Study Efficacy and Safety of Pedicled Lateral Chest Wall Lymph-Adipofascial Flap Axillary Reconstruction for the Prevention of Breast Cancer-Related Arm Lymphedema: A Prospective, Single-Arm, Phase II Clinical Study

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Not yet recruiting
    Registry
    NCT07415200

  86. Study A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

    Lead investigator
    Huijin Wang · Director of Thyroid and Breast Disease Center
    Hospital
    Guangzhou Women and Children's Medical Center
    Status
    Not yet recruiting
    Registry
    NCT06733233

  87. Study Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Status
    Not yet recruiting
    Registry
    NCT07697443

  88. Study A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.

    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07177950

  89. Study A Prospective, Double-Arm Study on the Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Lead investigator
    xuliang · professor
    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07527806

  90. Study Prospective Evaluation of Sentinel Lymph Node Biopsy Combined With Wire Localized Lymph Node Biopsy for Omitting Axillary Lymph Node Dissection in Breast Cancer Patients With 1-2 Sonographically Abnormal Lymph Nodes: A Diagnostic Study

    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07791771

  91. Study Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Status
    Not yet recruiting
    Registry
    NCT05505812

  92. Study A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+/HER2- Early Breast Cancer Using Real-World Data

    Lead investigator
    Jianyi Li · Principal Investigator
    Hospital
    Shengjing Hospital
    Status
    Not yet recruiting
    Registry
    NCT07484763

  93. Study An Exploration of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery

    Lead investigator
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT06811857

  94. Study A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study of Paclitaxel Polymeric Micelles Combined With Trastuzumab and Pertuzumab (HP) and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer

    Lead investigator
    Jian Zhang,MD · Director of Phase I Unit，Chief physician of oncology department
    Hospital
    Fudan University Shanghai Cancer Center
    Status
    Not yet recruiting
    Registry
    NCT07581795

  95. Study A Multicenter, Prospective, Randomized Phase II Trial Evaluating Trastuzumab, Pertuzumab, Docetaxel Combined With QL1706 Versus Combined With Carboplatin as Neoadjuvant Therapy for Early or Locally Advanced HER2+ Breast Cancer

    Hospital
    Guangdong Provincial People's Hospital
    Status
    Not yet recruiting
    Registry
    NCT07246317

  96. Study Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

    Lead investigator
    Yingying Xu · Professor
    Hospital
    First Hospital of China Medical University
    Status
    Not yet recruiting
    Registry
    NCT07305246

  97. Study TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

    Lead investigator
    Yingying Xu · Professor
    Hospital
    First Hospital of China Medical University
    Status
    Not yet recruiting
    Registry
    NCT07271992

  98. Study Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

    Lead investigator
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hospital
    Beijing Tiantan Hospital, Capital Medical University
    Status
    Not yet recruiting
    Registry
    NCT07458646

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 5 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Breast Surgery 乳腺恶性肿瘤多学科精准诊疗平台（普通外科） Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Breast Surgery 乳腺外科 Level A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Shandong Cancer Hospital山东省肿瘤医院 Jinan 济南市 Breast Surgery 乳腺外科 Level A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Hubei Cancer Hospital湖北省肿瘤医院 Wuhan 武汉市 Breast Surgery 乳腺中心 Level B https://www.hbch.com.cn/category/1-11.html
Hunan Cancer Hospital湖南省肿瘤医院 Changsha 长沙市 Breast Surgery 乳腺癌诊疗中心（国家级建设项目） Level B https://hnca.org.cn/wap/zdks/

5 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 10 ICD codes
Version Code Name in that version
ICD-10-WHO C50 Malignant neoplasm of breast
ICD-10-WHO C50.0 Nipple and areola
ICD-10-WHO C50.1 Central portion of breast
ICD-10-WHO C50.2 Upper-inner quadrant of breast
ICD-10-WHO C50.3 Lower-inner quadrant of breast
ICD-10-WHO C50.4 Upper-outer quadrant of breast
ICD-10-WHO C50.5 Lower-outer quadrant of breast
ICD-10-WHO C50.6 Axillary tail of breast
ICD-10-WHO C50.8 Overlapping lesion of breast
ICD-10-WHO C50.9 Breast, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24